Purpose of review Neuromuscular blocking agents (NMBAs) are part of the pharmaceutical arsenal employed to treat acute respiratory distress syndrome (ARDS). However, their use remains controversial because the potential benefits of these agents are counterbalanced by possible adverse effects. This review summarizes advantages and risks of NMBAs based on the most recent literature.
INTRODUCTION
Mortality in patients with acute respiratory distress syndrome (ARDS) remains high [1] despite significant advances, particularly in the management of mechanical ventilation [2, 3] . One of the common nonventilatory strategies used in the treatment of ARDS is administration of neuromuscular blocking agents (NMBAs) [4] . There are no recent guidelines concerning the indication for use of NMBAs in ARDS [5] , and use of these agents is controversial because of possible side effects, especially the development of ICUacquired weakness [6] . However, interest in NMBAs has increased after a recent randomized controlled trial (RCT) [7] showed a reduction in 90-day adjusted mortality after a 48-h continuous infusion of cisatracurium besilate in the most severe ARDS patients. The debate on NMBAs has been revived, and the purpose of this review of the literature is to highlight the benefits and risks of NMBA use in ARDS.
BENEFITS OF NEUROMUSCULAR BLOCKING AGENTS IN ACUTE RESPIRATORY DISTRESS SYNDROME PATIENTS: WHAT IS THE EVIDENCE?
tidal Volume and increased End-expiratory volume to Obviate Lung Injury trial [8] , NMBAs were used in 45 and 33% of patients in the lower and higher positive end-expiratory pressure (PEEP) groups, respectively [9] . A recent review reported that 25-55% of ARDS patients received adjuvant NMBAs [10] . One of the main reasons to justify the use of NMBAs in ARDS is facilitation of mechanical ventilation and control of patient/ventilator asynchrony [6,11 & ]. Paralysing the patient to facilitate 'controlled ventilation' could prevent patientventilator dyssynchrony, improve adaptation to mechanical ventilation and enable tolerance of 'permissive' hypercapnia [12] . Indeed, even deep sedation is often not enough to control minute ventilation, plateau pressure and tidal volume in the first phase of ARDS. Arroliga et al. [9] showed that the factors associated with NMBA use were mainly related to the severity of the disease, as assessed by a high Acute Physiology, Age, Chronic Health Evaluation III score. Moreover, NMBAs are often used for prone positioning, high PEEP levels or nonconventional modes of ventilation, such as high-frequency oscillatory ventilation [13] .
Improvement of oxygenation
Hypoxaemia is one of the most common reasons to use paralysing agents during ARDS [5] . In the early eighties, an improvement of oxygenation after administration of NMBAs was reported [14, 15] , but these results were not confirmed by subsequent studies [16] . A more recent study [17] reported an improvement in the P a O 2 /F i O 2 ratio in ARDS patients 30 min and 2 h after introducing a continuous infusion of cisatracurium (GlaxoSmithKline, Uxbridge, UK). However, these studies lacked methodological reliability, either because of their design or the small number of patients included. In the past 10 years, the first RCT was published on the effect of NMBAs on oxygenation during ARDS, which served as the basis for strong support of their use in this setting.
There are, however, only three RCTs in the setting of lung-protective ventilation, and they were conducted by the same group of investigators (Table 1 ). The first trial was conducted by Gainnier et al. [18] on 56 patients with ARDS. In this multicentre RCT, patients treated with NMBAs for 48 h had a significant improvement in their P a O 2 /F i O 2 ratio compared to the placebo group. Patients randomized to the NMBA group had a higher P a O 2 /F i O 2 at 48, 96 and 120 h after randomization. In contrast, there was not a change in the P a O 2 /F i O 2 ratio 1 h after randomization in the NMBA group. In a second multicentre, prospective, RCT designed to analyse the effects on inflammation of an early 48-h cisatracurium infusion in ARDS patients, the same group [19] confirmed a beneficial effect of NMBAs on oxygenation in 36 ARDS patients. A decrease in plateau pressure and PEEP and FiO 2 requirements during the 120-h study period were more marked in the NMBA group. Recently, the ARDS et curarisation systematique (ACURASYS) study [7] confirmed these results and amplified them, showing not only that the P a O 2 /F i O 2 ratio on day 7 was higher in patients receiving a 48-h continuous cisatracurium infusion than in the control group, but this was also the first RCT to demonstrate that NMBAs reduced mortality associated with ARDS.
Reduction of mortality
In the first two RCTs [18, 19] , there was a strong tendency toward a reduction in the mortality rate for patients receiving cisatracurium compared with the placebo group. However, these two trials were designed to explore physiological and/or biological effects. The ACURASYS study was the very first trial designed to evaluate the effect of NMBAs on mortality. In this multicentre, double-blind trial [7] , 339 patients presenting with severe ARDS within the previous 48 h (i.e. a P a O 2 /F i O 2 ratio <150 mmHg with PEEP !5 cm H 2 O) were randomly assigned to receive either cisatracurium besylate (177 patients) or placebo (162 patients) for 48 h. The group of patients treated early with cisatracurium for 48 h showed an improvement in the adjusted 90-day survival rate compared with those who received placebo. After adjusting for the baseline P a O 2 /F i O 2 ratio, plateau pressure and the Simplified Acute Physiology Score II, the hazard ratio for death at 90 days in the cisatracurium group, compared with the placebo group, was 0.68 [95% confidence interval (CI) 0.48-0.98; P ¼ 0.04]. Furthermore, the crude mortality rate at 28 days was 23.7% in patients who received cisatracurium and 33.3% in those who received placebo (P ¼ 0.05) ( Fig. 1 is noteworthy that the beneficial effect of cisatracurium on mortality was limited to the patients presenting a P a O 2 /F i O 2 ratio of less than 120. Among these patients, the 90-day mortality was 30.8% in the cisatracurium group and 44.6% in the control group (P ¼ 0.04) [7] . With respect to the secondary endpoints, patients in the cisatracurium group had significantly more ventilator-free days than those in the placebo group during the first 28 and 90 days and more days free of organ failure (other than the lung) during the first 28 days. Patients in the cisatracurium group had also fewer pneumothoraces than those in the placebo group (11.7 vs. 4.0% in the cisatracurium group; P ¼ 0.01).
Possible mechanisms of action explaining the beneficial effects
The observed improvements in mortality and gas exchange raise the question of the mechanisms involved. There are several potential pathophysiological pathways involved, and they are likely interrelated. Slutsky [12] proposed that paralysing agents could limit ventilator-induced lung injury (VILI), decrease blood flow to active muscle groups and improve arterial oxygenation, have a direct or indirect anti-inflammatory effect and decrease the occurrence of multiorgan failure by limiting biotrauma.
NMBAs modify thoraco-pulmonary mechanics and could improve the ventilation-to-perfusion ratio. The increase in thoraco-pulmonary compliance in ARDS can increase the functional residual capacity (FRC) and decrease the intrapulmonary shunt [20] .
The positive effects of NMBAs could also be related to a decrease in VILI (i.e. atelectrauma, barotrauma, volutrauma and biotrauma) [21] , as shown by the decreased incidence of barotrauma and pneumothoraces in the cisatracurium group in the ACURASYS study. It is now accepted that lung-protective mechanical ventilation decreases inflammation and mortality in patients with ARDS [22] . NMBA use could reinforce this beneficial effect of lung-protective mechanical ventilation in patients with ARDS through a reduction in biotrauma. This hypothesis was supported by Forel et al. [19] . In this study, 48 h after randomization, pulmonary concentrations of IL-1b, IL-6 and IL-8, as well as serum concentrations of IL-1b and IL-6 were lower in the NMBA group than in the control group. This finding is reinforced by the decrease in number of organ failures for patients in the cisatracurium group of the ACURASYS study, possibly as a result of less biotrauma [7] . Nevertheless, the direct anti-inflammatory effects of NMBAs remain unclear.
NMBAs could help to avoid patient-ventilator dyssynchrony and limit end-expiratory collapse by inhibiting active expiration, limiting derecruitment and maintaining PEEP [12] . Moreover, in some patients, inspiratory efforts could lead to global or regional increases in transpulmonary pressure (TPP) that can be deleterious [23 & ]. In lavage-injured rabbits, Yoshida et al. [23 & ] showed that spontaneous breathing efforts associated with moderate tidal volumes (7-9 ml/kg) generating high TPP were associated with significant lung injuries, even when the plateau pressure was maintained below 30 cmH 2 O.
These recent data from the literature provide a strong argument for beneficial effects of NMBAs during the early phase of severe ARDS, and support the use of a 48-h infusion of cisatracurium in patients with more hypoxaemic ARDS (particularly with a P a O 2 /F i O 2 ratio <120 mmHg). However, risks of using NMBAs have been reported and have resulted in controversy regarding the use of these agents for patients with ARDS. These risks warrant further attention.
RISKS ASSOCIATED WITH NEUROMUSCULAR BLOCKING AGENT USE: ARE THE BENEFITS WORTH THE RISKS?
Side effects of NMBAs in ICU patients have been a topic of discussion over the past 10 years. Figure 2 illustrates the main benefits and risks described in the literature.
ICU-acquired weakness
In a recent review evaluating the importance of polyneuropathy and myopathy in critical care, the incidence of ICU-acquired weakness was 34-60% in patients with ARDS [24 && ]. ICU-acquired weakness is responsible for severe and durable morbidity, such as limb and diaphragm weakness, that can persist for months or even years after discharge from the ICU [25] . As a result, since it was first described in the early eighties, ICU neuromyopathy has become a major concern [26] . Risk factors have been discussed in the literature. Some independent risk factors include female sex, multiple organ dysfunctions (!2), duration of mechanical ventilation and administration of corticosteroids [27] . It would appear that immobilization (favoured by NMBAs) renders the muscles more sensitive to the action of corticoids [28] . Glucocorticoids have catabolic effects on skeletal muscles and induce muscle atrophy [29] . Moreover, Kindler et al. [30] showed an additive effect of methylprednisolone or hydrocortisone and vecuronium on the acetylcholine receptor. Duration of vasopressor support, duration of ICU stay, hyperglycaemia, low serum albumin and neurological failure have also been identified as risk factors [31] [32] [33] . Bercker et al. [34] demonstrated that blood glucose levels during 28 days of an ICU stay were significantly higher in patients who developed neuromyopathy than in control patients. With respect to NMBAs, the literature is contradictory. Axonal neuropathies have rarely been associated with only NMBA administration. In a population of 95 patients, De Jonghe et al. [35] found that NMBAs were not associated with muscular weakness. In a recent prospective observational study performed in 40 ICUs, Weber-Carstens et al. [36] showed that NMBA use was not a significant risk factor for the development of impaired muscle membrane excitability. It is noteworthy that the association between NMBAs and corticosteroids seems to favour neuromuscular lesions. Griffiths and Hall [37] reported that simultaneous use of NMBAs and corticosteroids could be associated with muscle weakness, whereas NMBA use alone was not identified as an independent risk factor. In the ACURASYS study [7] , the incidence of ICU-acquired paresis (evaluated based on the Medical Research Council [27] score on day 28 or at the time of ICU discharge) was not higher in patients receiving a 48-h continuous cisatracurium infusion than in the control group. However, in one study, the use of NMBAs was an independent factor for ICU-acquired myopathies, but this study was performed on septic patients with multiple organ dysfunction, which is itself a risk factor for ICU weakness [38] . Hermans et al. [39] also identified NMBAs as an independent risk factor. Steroid compounds [vecuronium, pancuronium, rocuronium (Organon Pharmaceuticals, Roseland, NJ, USA)] appear to further favour the occurrence of myopathies because of their structural analogy [40] . A length of infusion exceeding 48 h is also a risk factor [41] .
Increase in the duration of mechanical ventilation
In a retrospective study by Arroliga et al. [9] , authors reported that unlike the use of sedatives and opioids, the use of NMBAs was not associated with prolonged exposure to mechanical ventilation. Furthermore, in the ACURASYS [7] study, the cisatracurium group had significantly more ventilator-free days than the placebo group during the first 28 and 90 days.
Diaphragm paralysis and lung atelectasis
The effects of NMBAs on thoraco-pulmonary morphology have been investigated. Several studies indicate that the use of NMBAs associated with sedation could be responsible for the occurrence of lung atelectasis. This has been investigated particularly in patients with healthy lungs in whom atelectasis occurs rapidly after anaesthesia with muscular paralysis [21] . Tokics et al. [20] described the presence of a shunt located to the gravitydependent atelectatic lung regions during anaesthesia with muscle paralysis. Lung atelectasis linked to the loss of diaphragmatic tone was observed by Brismar et al. [42] . However, these morphologic abnormalities totally disappeared after the application of PEEP (10 cmH 2 O) for 5 min [43] . The improvement in oxygenation observed in RCTs does not support a deleterious effect of NMBA on lung aeration. Imaging studies in patients with severe ARDS are necessary to draw conclusions about the effects of NMBAs on aeration of the lung. 
Anaphylaxis risk
Hypersensitivity reactions occurring after administration of NMBAs are a major cause for concern. According to the US Food and Drug Administration (Reference ID 2867714), the main hypersensitivity symptoms that develop after administration of cisatracurium besilate are the following: hypotension 0.2%, flushing 0.2%, respiratory bronchospasm 0.2% and dermatological rash 0.1%. A recent survey [44] of hypersensitivity reactions observed during anaesthesia in 1253 French patients, all of whom experienced anaphylaxis, revealed that succinylcholine (n ¼ 226; 60.6%) was the NMBA that most commonly caused anaphylaxis, whereas cisatracurium caused this reaction very infrequently (n ¼ 22; 5.9%).
Insufficient sedation and memorizing
Paralysing patients highlights the problem of inadequate sedation. Hardin et al. [45] have demonstrated that patients receiving NMBAs were awake for 22% of the sleep period over a time span of 24 h. Neuromonitoring with continuous electro-encephalogram or a device, such as the Bispectral Index (BIS, Aspect Medical Systems, Natick, MA, USA), could reduce the risk of consciousness in paralysed patients [46] . A recent prospective controlled study [47] showed that a neuromuscular blocker did not alter the BIS score in deeply sedated patients, suggesting that this may be a reliable tool to monitor the level of sedation in paralysed patients.
Post-traumatic distress syndrome
Nelson et al. [48] investigated the relation between the use of NMBAs during acute lung injury (ALI) and the quality of life of survivors in a retrospective study of 24 patients, questioned 6-41 months after treatment in the ICU. Interestingly, post-traumatic stress disorder symptoms were positively correlated with days of sedation and days of NMBA use, but not with initial severity of illness. A possible explanation is that patients who were on NMBAs for longer periods were the same patients with the most complicated ICU course, which would increase the likelihood of exposure to distressing experiences.
CONCLUSION
Recent studies indicate that the use of NMBAs during the early phase of ARDS, especially in the most hypoxaemic patients (patients with a P a O 2 /F i O 2 ratio <120 mmHg), improves oxygenation and decreases the 90-day mortality rate. The risks associated with the use of NMBAs can be limited by shortening the duration of administration to the first 48 h of ARDS. Administration of NMBAs does not appear to be an independent risk factor for ICUacquired weakness if they are not given with corticosteroids or in patients with hyperglycaemia. The mechanisms underlying the beneficial effects of NMBAs remain unclear, and future studies will be necessary to investigate them further. However, the administration of NMBAs for 48 h in patients with early and severe ARDS appears to be beneficial and well tolerated and may be included in future recommendations.
